|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
M.D. Anderson Cancer Center |
| Information provided by: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00071396 |
Purpose
The goal of this clinical research study is to learn if giving CAMPATH-1H with rituximab can shrink or slow the growth of the disease in patients with chronic lymphoid disorders that have either not responded or whose disease has returned after treatment with standard therapies.
| Condition | Intervention | Phase |
|
Chronic Lymphocytic Leukemia |
Drug: Campath-1H Drug: Rituximab |
Phase II |
| MedlinePlus related topics: | Cancer Leukemia, Adult Acute Leukemia, Adult Chronic Leukemia, Childhood |
| Drug Information available for: | Rituximab Alemtuzumab Campath |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | Continuous Infusion Followed by Subcutaneous Injection of Campath-1H Plus Rituximab in the Treatment of CD52- and CD20-Positive Refractory or Relapsed Chronic Lymphoid Disorders |
| Estimated Enrollment: | 48 |
| Study Start Date: | October 2002 |
| Estimated Study Completion Date: | November 2005 |
Objectives:
Eligibility
| Ages Eligible for Study: | 15 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Patients with above mentioned histologies whose malignant cell population have expressed both CD52 and CD20 in >/= 20% of cells as assessed by flow cytometry or immunohistochemistry. Expression of CD20 or CD52 < 20% is permitted if patients received either rituximab and/or Campath-
1H on different protocols but not in combination are eligible for the study.
Contacts and Locations| United States, Texas | |||||
| University of Texas - MD Anderson Cancer Center | |||||
| Houston, Texas, United States, 77030 | |||||
| M.D. Anderson Cancer Center |
| Principal Investigator: | Alessandra Ferrajoli, MD | M.D. Anderson Cancer Center |
More Information
M.D. Anderson Cancer Center's website 
  |
| Study ID Numbers: | ID02-368 |
| First Received: | October 21, 2003 |
| Last Updated: | October 6, 2006 |
| ClinicalTrials.gov Identifier: | NCT00071396 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|
|